Clever Culture Systems (CC5) investor relations material

Opening remarks and agenda

• Chair welcomed attendees, acknowledged traditional custodians, and confirmed quorum for the meeting.

• Meeting procedures, voting rights, and poll process for all resolutions were outlined.

• Board members, auditors, and registry representatives were introduced; notice of meeting was confirmed as read.

Financial performance and commercial traction

• Achieved maiden FY25 profit of $1.7 million, driven by $6.6 million in product sales and $1 million in high-margin recurring revenue.

• Achieved profitability and positive cash flows in FY25, strengthening the balance sheet.

• Cash and current receivables as of September 2025 total $5.5 million.

• Blue-chip pharmaceutical customers underpin profit and sales pipeline, with qualified leads estimated at $75 million upfront and $15 million recurring revenue potential.

• 99% of outstanding options exercised, raising AUD 1.1 million and enabling full loan repayment.

Product innovation and pipeline

• APAS® technology automates high-volume environmental monitoring tests, reducing manual labor and compliance risks.

• Launch of contact plates in Q1 FY26 will automate the majority of environmental monitoring tests, expanding the sales pipeline.

• Launched APAS Analysis Module for 55mm contact plates, expanding automation capabilities and recurring revenue potential.

• Imaging platform and AI software modules are compatible with multiple hardware configurations, enabling rapid scaling.

• Exploring development of a smaller instrument to broaden market reach, with funding and timing under consideration.